The Impact of Early-diagnosed New-onset Post-transplantation Diabetes Mellitus on Survival and Major Cardiac Events
Overview
Affiliations
The impact of early-diagnosed new-onset post-transplantation diabetes mellitus (PTDM) on cardiovascular (CV) disease is not well described. The objectives of the present prospective single-center observational study were to assess the long-term effects of early-diagnosed new-onset PTDM on major cardiac events (MCE; cardiac death or nonfatal acute myocardial infarction) and patient survival. Diabetic status and CV risk factors were assessed in 201 consecutive renal allograft recipients 3 months after transplantation (baseline) during a period of 16 months (1995-96). Follow-up data until January 1, 2004 were obtained from the Norwegian Renal Registry. The 8-year (range 7-9 years) cumulative incidence of MCEs was 7% (nine out of 138) in recipients without diabetes, 20% (seven out of 35) in patients with new-onset PTDM and 21% (six out of 28) in patients with diabetes mellitus before transplantation (DM). Proportional hazards regression analyses (forward stepwise regression) revealed that patients with PTDM had an approximately three-fold increased risk of MCEs as compared with nondiabetic patients (hazard ratio (HR)=3.27, 95% confidence interval (CI)=1.22-8.80, P=0.019). A total of 61 patients (30%) died. Eight-year patient survival was 80% in the nondiabetic group, 63% in the PTDM group and 29% in the DM group, respectively. Pretransplant diabetes (HR=5.09, 95% CI=2.60-9.96, P<0.001), age (HR=1.03, 95% CI=1.01-1.05, P=0.016), cytomegalovirus (CMV) infection (HR=2.66, 95% CI=1.27-5.53, P=0.009), and creatinine clearance (HR=0.98, 95% CI=0.96-1.00, P=0.046), but not PTDM (HR=1.20, 95% CI=0.58-2.49, P=0.621), were independent predictors of death in the multiple Cox regression model. Early-diagnosed PTDM is a predictor of MCEs, but not of all-cause mortality, the first 8 years after renal transplantation.
Arabi Z, Alghamdi H, Arabi T, Shafqat A, Elwy B, Sabbah B Ther Adv Endocrinol Metab. 2024; 15:20420188241301940.
PMID: 39619270 PMC: 11607771. DOI: 10.1177/20420188241301940.
Park S, Koo B, Park S, Han K, Moon M Diabetes Metab J. 2024; 49(1):117-127.
PMID: 39262290 PMC: 11788551. DOI: 10.4093/dmj.2024.0078.
SMART DIABETES HOSPITAL: CLINICAL IMPACT IN COMPLEX SURGICAL UNITS OF A TERTIARY HOSPITAL.
Simo-Servat O, Amigo J, Ortiz-Zuniga A, Sanchez M, Cuadra F, Santos M Acta Diabetol. 2024; 62(3):423-428.
PMID: 39240308 PMC: 11872769. DOI: 10.1007/s00592-024-02370-6.
Posttransplant complications: molecular mechanisms and therapeutic interventions.
Liu X, Shen J, Yan H, Hu J, Liao G, Liu D MedComm (2020). 2024; 5(9):e669.
PMID: 39224537 PMC: 11366828. DOI: 10.1002/mco2.669.
Kanbay M, Siriopol D, Guldan M, Ozbek L, Topcu A, Siriopol I Nephrol Dial Transplant. 2024; 40(3):554-576.
PMID: 39134508 PMC: 11879034. DOI: 10.1093/ndt/gfae185.